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Abstract 
Background: The impact of hemoglobin levels and anemia on stroke mortality remains 
controversial. We aimed to systematically assess this association and quantify the evidence. 
Methods and Results: We analysed data from a cohort of 8,013 stroke patients (mean (sd) 
77.81±11.83 years) consecutively admitted over 11 years (January 2003–May 2015) using a 
UK Regional Stroke Register.  The impact of hemoglobin levels and anemia on mortality was 
assessed by sex-specific values at different time points (7-day, 14-day, 1-month, 3-month, 6-
month, 1 year), using multiple regression models controlling for confounders. Anemia was 
present in 24.5% of the cohort on admission and was associated with increased odds of 
mortality at most of the time points examined up to 1 year following stroke. The association 
was less consistent for males with hemorrhagic stroke.  Elevated haemoglobin was also 
associated with increased mortality, mainly within the first month. We then conducted a 
systematic review using the EMBASE and Medline databases. Twenty studies met the 
inclusion criteria.  When combined with the cohort from the current study, this gave a pooled 
population of 29,943 patients with stroke. The evidence base was quantified in a meta-
analysis. Anemia on admission was found to be associated with an increased risk of mortality 
in both ischemic stroke (8 studies); OR 1.97(1.56– 2.47) and hemorrhagic stroke (4 studies); 
OR 1.46(1.23–1.74). 
Conclusions: There is strong evidence that patients with anemia have increased mortality in 
stroke. Targeted interventions in this patient population may improve outcomes and therefore 
require further evaluation.  
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Introduction 
Anemia is common in patients presenting with acute stroke. Hospital based studies 
reported prevalence up to ~ 30% [1, 2]. While anemia has been independently associated with 
increased mortality in a variety of conditions including chronic kidney disease [3], heart 
failure[4] and acute coronary syndromes[5], observational studies investigating the 
association between anemia and mortality in stroke have shown conflicting results. Early 
studies found no association between anemia and stroke outcomes [6, 7], however, others 
have found both low and high hemoglobin levels to be associated with increased mortality [8 
-10] suggesting a U-shaped relationship. Guidelines have so far been unable to specify the 
optimal treatment options in acute stroke patients with anemia[11].  
Previous studies were limited by small sample sizes and a majority of them did not 
report outcomes by stroke subtype. In addition, no previous study stratified analysis by sex-
specific hemoglobin levels. This is particularly important due to the natural variance in the 
normal hemoglobin ranges between sexes. The literature describes various plausible 
mechanisms which explain how anemia could directly contributes to poor outcomes [12]. 
However, there is a paucity of information investigating the impact of an important clinical 
factor; whether stroke patients with anemia receive less preventative medications pertinent to 
stroke such as antiplatelets and anticoagulants (antithrombotics). In addition, there is a lack of 
data with regard to the co-morbidity burden in anemic stroke patients and inadequate 
controlling for this in statistical analyses.  
The current study aimed to clarify these important questions by assessing the impact 
of admission hemoglobin levels and anemia on stroke mortality at different time points, up to 
one-year follow-up. A systematic review and meta-analysis was also carried out in order to 
further quantify the impact of admission hemoglobin/anemia on stroke mortality outcomes. 
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Methods 
Database study 
The study population consisted of 8,013 patients with acute stroke, consecutively 
admitted between January 2003 – May 2015 to Norfolk and Norwich University Hospital, a 
regional tertiary center in East Anglia, UK, with a catchment population of approximately 
750,000. Ethical approval was obtained from the Newcastle and Tyneside National Health 
Service (NHS) Research Ethics Committee (12/NE/0170) and the study protocol was 
approved by the Steering Committee of the Register.   
The data collection methods for this prospective hospital-based register have been 
previously reported[13]. Briefly, the data were obtained from paper and electronic records, 
reviewed and then entered onto the register database. This was done by the hospital stroke 
data team and vetted by clinical team members for accuracy. For each patient admitted, the 
pre-stroke modified Rankin score (mRS) (see footnote Table 1), as modified by UK-TIA 
investigators [14], was ascertained from nursing and medical records by stroke specialist 
nurses. At discharge, the dead or alive status was recorded to capture in-hospital mortality. 
Follow-up for mortality was obtained by electronic record linkage with Office of National 
Statistics data through hospital episodes in May 2015. For the purposes of this study, the 
follow-up was truncated at 365 days for all patients.   
The variables included were age, sex, stroke sub-type (ischemic/hemorrhagic), pre-
stroke disability depicted by mRS (0 – 5), Oxfordshire Community Stroke Project (OCSP) 
classification (Total Anterior Circulation Stroke, Partial Anterior Circulation Stroke, 
Posterior Circulation Stroke, Lacunar Stroke), hemoglobin levels at admission, co-
morbidities (Coronary Heart Disease, Congestive Heart Failure, Atrial Fibrillation, 
Hypertension, Hyperlipidemia, Previous Stroke, Diabetes Mellitus, Peripheral Vascular 
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Disease, Gastrointestinal Bleeding, Peptic Ulcers, Chronic Obstructive Pulmonary Disease, 
Chronic Kidney Disease, Falls, Malignancy, Dementia) and prior use of antithrombotics. 
Mortality was assessed at several different time points; in patient, 7 days, 14 days, 1 month, 3 
months, 6 months and 1 year. However, results were displayed selectively in Tables 2 and 3 – 
data for the 7 and 14 day time points was not included due to the similarity in results and in 
order to ensure brevity.  Only confirmed cases of stroke were included. Stroke was diagnosed 
using evidence from clinical features and neuroimaging (typically CT and in some cases 
MRI). Anemia was defined according to the WHO criteria of Hb <12.0 g/dL in females and 
<13.0 g/dL in males and elevated hemoglobin was defined as >15.5g/dL in females and 
>17.0g/dL in males[15].  
The associations between hemoglobin levels and age, sex, pre-stroke mRS, stroke 
type, OCSP classification, co-morbidities, prior antithrombotic use and inpatient mortality 
were assessed using chi-squared test. Logistic regression models were constructed to assess 
the impact of hemoglobin levels (by quintiles) and anemia on odds of death.  Univariate and 
multivariate models were used to calculate unadjusted and adjusted odds ratios. Sex and 
stroke type specific analyses were performed controlling for age, OCSP classification, pre-
stroke mRS, co-morbidities and prior antithrombotic usage.  
To better understand the potential mediating factors for the observed associations, we 
examined the distribution of selected chronic co-morbidities between patients with anemia 
and no anemia and also assessed the differences in proportions of patients receiving 
antithrombotic medications by a vascular indication (defined as presence of previous Stroke, 
Coronary Heart Disease, Diabetes Mellitus, Peripheral Vascular Disease, Hypertension and 
Atrial Fibrillation). The analysis was performed using the SPSS Version 23.0 (SPSS Inc., 
Chicago, Illinois, USA).  
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Systematic review and meta-analysis 
We selected full journal articles reporting on studies that evaluated the association between 
baseline hemoglobin or anemia and subsequent mortality in patients diagnosed with stroke. 
PubMed and EMBASE were searched from inception until December 2014 using the terms 
shown in Figure 1, with no language restriction. In addition, we checked the bibliographies of 
relevant articles for any studies that met our selection criteria.  
Two reviewers (RB and KH) independently screened abstracts and titles. Potentially 
relevant studies were reviewed in order to confirm their eligibility. The selection and data 
extraction of included studies was performed by RB and KH and checked by a senior 
reviewer, YKL. In order to assess study validity, included studies were assessed for the 
following; methods used for diagnosing stroke, determination of hemoglobin levels and 
anemia, ascertainment of mortality/outcome subsequent to the stroke and the analytic 
procedures aimed at minimizing the risk of bias from confounders. We pooled the reported 
associations (adjusted odds ratio where available) using the inverse variance method and 
random effects model in RevMan 5.3 software (Nordic Cochrane Center, Copenhagen, 
Denmark). The comparisons of interest were for categories of anemia versus no anemia, in 
patients with ischemic and hemorrhagic stroke, versus the referent normal category. We 
evaluated heterogeneity by calculating the I2 statistic, whereby a value >50% was indicative 
of substantial heterogeneity. We also aimed to check for publication bias through a funnel 
plot if there were more than 10 eligible studies in our systematic review. 
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Results 
Database study 
Of the 11,886 episodes recorded in the registry, 3,873 were excluded due to various reasons, 
which are presented in Figure 2. 2,659 of these patients were excluded due to missing data 
and 991 were excluded because they were episodes which related to secondary entry into the 
register due to subsequent stroke. The sample included in the current study consisted of 8,013 
patients with acute stroke, admitted consecutively between January 2003 – May 2015. The 
mean age in the cohort was 77.81 ± 11.83, with 52.4% females, and 86.7% had ischemic 
stroke. The most common OCSP stroke classification was PACS (33.1%) and the majority of 
patients (62.6%) had a pre-stroke mRS of 0. Inpatient mortality was 21.3% and 1 in 4 patients 
(24.5%) had anemia on admission.  
Table 1 shows sex-specific sample characteristics by anemia status. Increasing age, 
higher pre-stroke disability, increased stroke severity, inpatient mortality and all co-
morbidities (with the exceptions of Hyperlipidemia in females) were associated with anemia 
(see Figures 3 & 4). Prior antithrombotic use in males and ischemic stroke in females were 
also associated with anemia. 
Table 2 depicts the impact of hemoglobin levels on stroke mortality by quintiles of 
sex-specific admission hemoglobin levels, presented separately for ischemic and hemorrhagic 
stroke. Quintile 1 contains those with the lowest values and Quintile 5 with the highest. The 
cut-off points were 12.40, 13.80, 14.64 and 15.60 (g/dL) for males and 11.70, 12.80, 13.60, 
14.50 (g/dL) for females. In males with ischemic stroke, low hemoglobin (Quintile 1) was 
significantly associated with increased mortality at all of the time points measured, compared 
to those with normal hemoglobin levels (Quintile 3). High hemoglobin (Quintile 5) was also 
associated with increased odds of mortality at four time points; inpatient, 7 days, 14 days and 
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1 month. This suggested a U-shaped relationship between hemoglobin levels and short-term 
mortality in males with ischemic stroke. In females with ischemic stroke, low hemoglobin 
levels were significantly associated with mortality at five time points; inpatient, 1 month, 3 
months, 6 months and 1 year. In females with hemorrhagic stroke, low hemoglobin levels 
were associated with increased mortality at all time points.  
Table 3 shows the impact of anemia and elevated hemoglobin levels on mortality. In 
males with ischemic stroke, anemia was associated with higher odds of death at all time 
points assessed and elevated hemoglobin was associated with increased odds of death at 3 
time points; inpatient, 1 month and 3 months. In males with hemorrhagic stroke, anemia was 
associated with increased mortality at 1 year and elevated hemoglobin was associated with 
increased mortality at four time points; inpatient, 7 days, 14 days and 1 month. In females 
with ischemic stroke, anemia was associated with increased mortality at 1 month, 3 months, 6 
months and 1 year, while elevated hemoglobin was associated with increased mortality at 7 
days, 14 days and 1 month. In females with hemorrhagic stroke, anemia was associated with 
increased mortality at all time points assessed, while elevated hemoglobin was associated 
with increased mortality at three time points; inpatient, 6 months and 1 year.  
Table 4 depicts prior antithrombotic use by anemia status and vascular indication. In 
females with a positive vascular indication, those with anemia were less likely to be on prior 
antithrombotics compared to those without anemia (p-value 0.032). Conversely, in males 
with a negative vascular indication, those with anemia were more likely to be on prior 
antithrombotics than those without anemia (p-value <0.001).  In addition, anemia was 
associated with increased co-morbidity burden in both sexes (Figures 3 & 4) 
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Systematic review and meta-analysis 
Our search identified 1,424 citations. After detailed screening, 20 studies were 
included in our systematic review; the flow chart of study selection is shown in Figure 5. Ten 
studies assessed the impact of anemia on stroke [1, 2, 10, 19 – 23, 26, 28] and ten evaluated 
the association between stroke and hemoglobin levels [6 - 9, 16 - 18, 24, 25, 27]. In terms of 
study design, three were retrospective cohort studies[1, 22, 28], thirteen were prospective 
cohort studies[2, 6 - 10, 16 - 21, 26] and two were secondary analyses of a randomized 
control trials[24, 25]. There were also two studies which did not state their design [23, 27]. 
There was a high degree of geographical location, with cohorts from Germany[8, 18, 21], 
Switzerland[22, 28], United States[17, 20], China[2], Canada[16], India[6], Israel[10], South 
Korea[9], Denmark[23], Taiwan[19], United Kingdom[27] and Poland[7]. There were also 
three studies conducted across multiple states[1, 24, 25].  Regarding stroke type, nine studies 
assessed patients with ischemic stroke[1, 2, 8, 9, 19, 22 - 25], six assessed patients with 
hemorrhagic stroke[16 - 18, 20, 21, 26] and five evaluated both types of stroke[6, 7, 10, 27, 
28]. The number of participants in the studies ranged from 106 to 3,020. When combined 
with the participants from the current study, this resulted in a total pooled study population of 
29,943 participants of whom 24,816 were meta-analysed. Odds ratios included in the meta-
analysis were from the mortality time-point of 12 months, or the closest available to this. 
Tables 5 and 6 shows the key features of the selected studies. 
Validity Assessment 
Different methods were used for ascertainment of stroke diagnosis. Imaging (CT, MRI or 
both) was used in seventeen studies[1, 2, 6, 7, 10, 16 – 26], one study relied on clinical 
evaluation alone [27] and two did not state the method used[9, 28]. The methods used to 
ascertain mortality also varied. Attending doctors were used to confirm in-hospital mortality 
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in two studies[17, 18], while death registry data was used in three[10, 16, 23]. Telephone 
interviews were used by nine studies, typically in conjunction with other methods such as 
outpatient visit, home visit, mailed questionnaires, analysis of death registries or review of 
medical records[6, 8, 9, 20 - 22, 26, 28]. One study used outpatient visits only[19] and the 
method used to establish mortality status was unclear in six studies[1, 2, 7, 24, 25, 27].  
Despite the variety of approaches taken to ascertain mortality, none were notably unreliable.  
Eleven studies used the WHO definition of anemia as hemoglobin cut-offs[2, 8, 10, 
17, 19, 20 - 23, 26, 28], seven used pre-specified values [1, 9, 16, 18, 24, 25, 27] and two did 
not specify the values used[6,7]. By using pre-specified thresholds in constructing categorical 
comparisons for anemia, it is possible that cut-points have been drawn up which favour 
statistically significant findings. Eighteen studies adjusted for potential confounders[1, 2, 6, 
7, 8, 10, 16 - 27], however, there was great variation in terms of the variables adjusted for. 
These ranged from age and NIHSS[1] to age, sex, insurance status, smoking, time to 
treatment, type of intervention, pre-stroke medication, body mass index, blood pressure, heart 
rate, TOAST classification, metabolic parameters and co-morbidities[22]. Many studies were 
therefore liable to residual confounding (Table 6).  
Meta-analysis of pooled results show anemia is associated with an increased risk of 
mortality in ischemic stroke; pooled OR of 1.97 (1.56 – 2.47) (Figure 6).We also found a 
significant association for the evaluation of anemia and mortality in hemorrhagic stroke, 
albeit at a lower magnitude of association; OR of 1.47 (1.23 – 1.74) (Figure 7).The number of 
studies providing ORs on the relationship between elevated hemoglobin and stroke mortality 
were insufficient for a meta-analysis to be carried out. While available data suggests elevated 
hemoglobin predicts short-term mortality in ischemic stroke, it is less consistent for 
hemorrhagic stroke (Table 7). The funnel plot, depicting odds ratios for mortality in anemic 
ischemic stroke patients, shows asymmetry (Figure 8), with an under-representation of 
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studies on the right side which we would typically expect to consist of those reporting no 
significant harm in the relationship between anemia and stroke mortality. We encountered 
five such studies that reported no significant association in our systematic review, which we 
could not incorporate into the meta-analysis because the odds ratios were not given, thus 
causing asymmetry in the funnel plot.  
 
Discussion  
Our study examined the association between anemia/hemoglobin levels and mortality 
in acute stroke in a large unselected stroke patient population and also sought to quantify this 
association using systematic review and meta-analysis. At 24.5%, anemia had a high 
prevalence in the cohort analysed in the current study. Low hemoglobin levels were 
associated with older age, increased stroke severity, higher pre-stroke disability and the 
increased co-morbidity burden. This suggested that outcomes were mediated by the impact of 
confounders. However, we found anemia to be independently associated with mortality, 
subsequent to making the appropriate adjustments. A systematic review and meta-analysis of 
the literature confirmed our findings. In addition, we found elevated hemoglobin to be 
associated with poorer outcomes in acute stroke suggesting a U-shaped relationship between 
hemoglobin levels and stroke mortality.  
The literature has described several pathological mechanisms which can plausibly 
explain the independent association between anemia and increased mortality risk in stroke. 
Firstly, by lowering the oxygen carrying capacity of blood, anemia may intensify ischemia 
and therefore hypoxia within the penumbral lesions in patients with ischemic stroke[29,30]. 
Secondly, anemia can compromise cerebrovascular autoregulation leading to fluctuations in 
cerebral perfusion, which in turn alters the delivery of oxygen to the brain[31, 32], thereby 
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exacerbating damage caused by ischemia or hemorrhage. Thirdly, augmentation of cerebral 
blood flow can create turbulence, which can in turn trigger the migration of an existing 
thrombus leading to a thromboembolism[33]. Fourthly, anemia may lead to hyperdynamic 
circulation, which has been shown to modulate the expression of adhesion molecules on 
vascular endothelial cells by upregulating their production. This may trigger an inflammatory 
response which leads to thrombus formation in a process similar to atherosclerosis[34, 35]. 
Fifthly, anemia may worsen outcomes in stroke due to its relationship with inflammatory 
mediators; it can upregulate the production of iNOS and CXCR4[36], both of which have 
been associated with brain damage during ischemia[37, 38]. 
In addition to the pathophysiological mechanisms described above, there is also a 
plausible clinical explanation for the excess mortality risk in stroke patients with anemia. It 
may be the case that anemic patients were less likely to be prescribed antithrombotics due to 
the increased risk of bleeding. This was suggested by the finding in Table 4, where fewer 
anemic females, who had a positive vascular indication, were on prior antithrombotics 
compared to those without anemia. This finding potentially supports the well documented 
differential management of cardiovascular risk factors between sexes. The reverse trends are 
observed for those without vascular indications thus supporting previous observations that 
inappropriate prescribing may be more prevalent in females.  
The association between anemia and mortality suggests that interventions may 
improve outcomes. While previous studies have shown packed red blood cell (pRBC) 
transfusions to reduce mortality at 30-days in anemic patients with myocardial infarction[39], 
a recent systematic review and meta-analysis found blood transfusion after percutaneous 
coronary intervention to be associated with adverse outcomes [40] thus casting doubt on the 
potential benefits of pRBC transfusions in anemic stroke patients. Observational studies 
reporting the association between mortality and transfusion in anemic patients with 
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hemorrhagic stroke have had varied results, with one finding a reduction in mortality [41] and 
another finding no change[18]. To the knowledge of the authors, no studies assessing the 
impact of pRBC transfusion on anemic ischemic stroke patients have been conducted. Due to 
the paucity of evidence, guidelines have been unable to specify hemoglobin targets or optimal 
management options [11]. A randomized controlled trial is required to gauge the impact of 
transfusions and establish optimum hemoglobin ranges in patients with acute stroke.  
Our study has a number of strengths. The stroke cases were prospectively identified 
and the cohort had an almost complete follow-up using validated methods.  As a large sample 
population was used, it was possible to conduct a rigorous analysis by sex and stroke type, 
enabling us to provide new insights. We were also able to control for a diverse array of 
confounders thereby mitigating the effects of residual confounding. The meta-analysis 
included individuals from a wide array of countries increasing the generalizability of our 
findings. The inclusion of a large number of participants in the meta-analysis provided 
sufficient statistical power to obtain results for both stroke sub-types. Finally, all studies 
included in the meta-analysis were of high methodological quality.   
This study has some limitations. The small sample number of patients with 
hemorrhagic stroke may have contributed to the non-significant p-values. Some of the 
models used did not fit the data well. Hosmer-Lemeshow tests were significant for  ischemic 
stroke in males at 3, 6 and 12 months (see Table 2). Although this does not alter the 
associations found it indicates that for this subgroup there may be other factors or interactions 
which might help better predict mortality outcome at these time points. It is therefore possible 
that we were not able to control for unknown factors. As a registry based study we were not 
able to fully adjust for treatment effect (e.g. blood transfusion, use of iron supplements and 
erythropoietin stimulating agents). Nonetheless, transfusion for mild to moderate anemia in 
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stroke is not a routine practice and the likelihood of such confounding is thus minimal. We 
were unable to take into account the duration of anemia or assess the impact of abnormal 
hemoglobin levels subsequent to a stroke. The independent association between anemia and 
excess mortality in stroke cannot, therefore, be described as a causal relationship. The studies 
in the meta-analysis had high heterogeneity for ischemic stroke (I2>50%). Finally, the 
possibility of under-representation of studies that reported no significant harm in the 
relationship between anemia and stroke mortality raises the possibility of selective reporting. 
As a consequence of this, our meta-analysis may over-inflate estimates of the association 
between anemia and excess mortality risk. 
To conclude, we have shown that a significant proportion of stroke patients have 
anemia at the time of stroke onset and that this is associated with increased mortality up to 
one year. The optimal treatment option in this patient group is unclear. Studies are required to 
examine the clinical and cost effectiveness of interventions in this patient population in an 
acute stroke setting.   
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Figure [1]. Search Strategy 
  
22 
 
Figure [2]. Patient Inclusion Chart 
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Figure [3]. Prevalence of Co-Morbidities by Anemia Status in Males 
 
The vertical line in the figure above represents the expected proportion of co-morbidity based on the proportion of stroke patients with anemia. 
Therefore any dark bars to the right of the vertical line represent higher co-morbidity burden in anemic patients compared with patients who 
were not anemic. 
 
73 
55 
54 
49 
49 
47 
44 
43 
43 
41 
41 
40 
32 
27 
45 
46 
51 
51 
53 
56 
57 
57 
59 
59 
60 
68 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
CKD
PVD
Dementia
Falls
CHF
Malignancy
Diabetes
COPD
Hyperlipidemia
AF
CHD
Hypertension
PreviousStroke
Anemia No Anemia
24 
 
Figure [4]. Prevalence of Co-Morbidities by Anemia Status in Females 
 
The vertical line in the figure above represents the expected proportion of co-morbidity based on the proportion of stroke patients with anemia. 
Therefore any dark bars to the right of the vertical line represent higher co-morbidity burden in anemic patients compared with patients who 
were not anemic. 
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Figure [5] Flow Diagram of Study Selection  
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Figure [6]. Meta-Analysis of Studies Analysing the Impact of Anemia on Admission on Mortality in Ischemic Stroke 
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Figure [7]. Meta-Analysis of Studies Analysing the Impact of Anemia on Admission on Mortality in Hemorrhagic Stroke 
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Figure [8]. Funnel Plot of Odds Ratios from Studies Analyzing the Impact of Anemia on Admission on Mortality in Ischemic Stroke 
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Table [1]. Sex-specific Sample Characteristics by Anemia Status  
 Male Female 
 Anemia No Anemia P-Value Anemia No Anemia P-Value 
Number 1,017 (26.7) 2,794 (73.3)  947 (22.5) 3,255 (77.5)  
Age   <0.001   <0.001 
≤ 60 46 (4.5) 424 (15.2)  29 (3.1) 208 (6.4)  
61 – 65 32 (3.1) 282 (10.1)  21 (2.2) 143 (4.4)  
66 – 70 50 (4.9) 340 (12.2)  33 (3.5) 231 (7.1)  
71 – 75 127 (12.5) 411 (14.7)  65 (6.9) 344 (10.6)  
76 – 80 187 (18.4) 470 (16.8)  137 (14.5) 522 (16.0)  
81 – 85 247 (24.3) 475 (17.0)  232 (24.5) 747 (22.9)  
86 – 90 234 (23.0) 279 (10.0)  253 (26.7) 635 (19.2)  
≥ 91 94 (9.2) 113 (4.0)  177 (18.7) 435 (13.4)  
Pre-stroke Comorbidity       
Coronary Heart Disease 304 (29.9) 446 (16.0) <0.001 230 (24.3) 475 (14.6) <0.001 
Previous Stroke 287 (28.2) 607 (21.7) <0.001 261 (27.6) 763 (23.4) 0.009 
Congestive Heart Failure 143 (14.1) 154 (5.5) <0.001 147 (15.5) 255 (7.8) <0.001 
Atrial Fibrillation 217 (21.3) 307 (11.0) <0.001 206 (21.8) 508 (15.6) <0.001 
Hypertension 422 (41.5) 650 (23.3) <0.001 393 (41.5) 1,044 (32.1) <0.001 
Hyperlipidaemia 76 (7.5) 99 (3.5) <0.001 42 (4.4) 135 (4.1) 0.698 
Diabetes Mellitus 183 (18.0) 231 (8.3) <0.001 137 (14.5) 242 (7.4) <0.001 
Peripheral Vascular 
Disease 
63 (6.2) 49 (1.8) <0.001 28 (3.0) 61 (1.9) 0.042 
GI Bleeding and Peptic 
Ulcer  
81 (8.0) 118 (4.2) <0.001 62 (6.5) 142 (4.4) 0.006 
COPD 90 (8.8) 113 (4.0) <0.001 65 (6.9) 107 (3.3) <0.001 
Chronic Kidney Disease 93 (9.1) 37 (1.3) <0.001 50 (5.3) 69 (2.1) <0.001 
Falls 161 (15.8) 160 (5.7) <0.001 275 (29.0) 557 (17.1) <0.001 
Malignancy 240 (23.6) 274 (9.8) <0.001 112 (11.8) 278 (8.5) 0.002 
Dementia 47 (4.6) 43 (1.5) <0.001    
Prior Antithrombotic Use   <0.001   0.286 
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           No 447 (44.0) 1,538 (55.0)  499 (52.7) 1,779 (54.7)  
           Yes 570 (56.0) 1,256 (45.0)  448 (47.3) 1,476 (45.3)  
Pre-stroke Rankin Score†   <0.001   <0.001 
0 556 (54.7) 2,119 (75.8)  388 (41.0) 1,955 (60.1)  
1 155 (15.2) 286 (10.2)  135 (14.3) 399 (12.3)  
2 96 (9.4) 147 (5.3)  121 (12.8) 303 (9.3)  
3 131 (12.9) 142 (5.1)  160 (16.9) 354 (10.9)  
4 54 (5.3) 73 (2.6)  90 (9.5) 176 (5.4)  
5 25 (2.5) 27 (1.0)  53 (5.6) 68 (2.1)  
Stroke Type   0.088   0.002 
Hemorrhagic 121 (11.9) 392 (14.0)  95 (10.0) 454 (13.9)  
Ischemic      896 (88.1) 2,402 (86.0)  852 (90.0) 2,801 (86.1)  
OCSP Classification   0.002   <0.001 
TACS 215 (21.1) 500 (17.9)  248 (26.2) 699 (21.5)  
PACS 359 (35.3) 900 (32.2)  312 (32.9) 1,084 (33.3)  
POCS 169 (16.6) 548 (19.6)  118 (12.5) 521 (16.0)  
LACS 209 (20.6) 696 (24.9)  186 (19.6) 786 (24.1)  
Undefined 65 (6.4) 150 (5.4)  83 (8.8) 165 (5.1)  
Inpatient Mortality   <0.001   <0.001 
Alive 731 (71.9) 2,393 (85.6)  635 (67.1) 2,546 (78.2)  
Dead 286 (28.1) 401 (14.4)  709 (21.8) 312 (22.5)  
*Hb = hemoglobin, OCSP = Oxfordshire Community Stroke Project, TACS = Total Anterior Circulation Stroke, PACS = Partial Anterior 
Circulation Stroke, POCS = Posterior Circulation Stroke, LACS = Lacunar Stroke, GI = Gastrointestinal 
† 0 = no symptoms. 
1 = no significant disability despite symptoms; able to carry out all usual duties and activities. 
2 = slight disability; unable to perform all previous activities but able to look after own affairs without assistance. 
3 = moderate disability; requires some help but able to walk without assistance. 
4 = moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance. 
5 = severe disability; bedridden, incontinent, and requiring constant nursing care and attention. 
‡The data presented are number (%) for categorical variables. 
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Table [2]. The Impact of Hemoglobin Levels on Mortality at Different Time Points (Logistic Regression) 
Variable Hb Quintile 1 Hb Quintile 2 Hb Quintile 3 Hb Quintile 4 Hb Quintile 5* Events 
Male Ischemic   
Number 635 675 667 644 677  
Inpatient 2.64 (1.83 – 3.81) 1.56 (1.08 – 2.25) 1.00 1.59 (1.06 – 2.38) 1.62 (1.08 – 2.42) 511 
1 Month 2.99 (2.06 – 4.34) 1.74 (1.19 – 2.53) 1.00 1.55 (1.03 – 2.34) 1.79 (1.19 – 2.68) 488 
3 Months 3.09 (2.24 – 4.25) 1.34 (0.96 – 1.85) 1.00 1.18 (0.82 – 1.69) 1.37 (0.96 – 1.95) 674 
6 Months 2.92 (2.16 – 3.94) 1.37 (1.01 – 1.85) 1.00 1.05 (0.75 – 1.46) 1.16 (0.83 – 1.63) 796 
1 Year 2.90 (2.18 – 3.86) 1.43 (1.08 – 1.90) 1.00 1.17 (0.86 – 1.59) 1.17 (0.86 – 1.60) 971 
Male Hemorrhagic   
Number 83 109 103 87 131  
Inpatient 1.23 (0.58 – 2.60) 0.83 (0.42 – 1.65) 1.00 0.86 (0.39 – 1.86) 1.05 (0.53 – 2.09) 176 
1 Month 1.22 (0.59 – 2.51) 0.92 (0.48 – 1.78) 1.00 0.81 (0.39 – 1.70) 0.93 (0.48 – 1.80) 173 
3 Months 1.16 (0.55 – 2.42) 0.67 (0.34 – 1.30) 1.00 0.76 (0.38 – 1.57) 0.68 (0.35 – 1.57) 200 
6 Months 1.65 (0.77 – 3.55) 0.81 (0.41 – 1.60) 1.00 0.78 (0.38 – 1.62) 0.73 (0.38 – 1.41) 221 
1 Year 1.97 (0.92 – 4.22) 0.81 (0.42 – 1.58) 1.00 0.73 (0.35 – 1.51) 0.79 (0.41 – 1.51) 229 
Female Ischemic  
Number 698 748 700 752 755  
Inpatient 1.47 (1.08 – 1.98) 1.05 (0.77 – 1.43) 1.00 1.39 (1.01 – 1.90) 1.20 (0.88 – 1.63) 792 
1 Month 1.48 (1.09 – 2.01) 1.16 (0.85 – 1.58) 1.00 1.23 (0.89 – 1.69) 1.26 (0.92 – 1.73) 733 
3 Months 1.70 (1.28 – 2.25) 1.16 (0.87 – 1.54) 1.00 1.34 (1.00 – 1.79) 1.19(0.89 – 1.58) 1007 
6 Months 1.86 (1.42 – 2.44) 1.22 (0.93 – 1.60) 1.00 1.44 (1.09 – 1.89) 1.26 (0.96 – 1.67) 1159 
1 Year 1.86 (1.44 – 2.41) 1.23 (0.96 – 1.59) 1.00 1.29 (0.99 – 1.68) 1.13 (0.87 – 1.46) 1328 
Female Hemorrhagic  
Number 72 100 132 127 118  
Inpatient 2.56 (1.23 – 5.32) 0.80 (0.41 – 1.57) 1.00 0.80 (0.54 – 1.81) 1.35 (0.74 – 2.47) 229 
1 Month 2.61 (1.31 – 5.36) 0.80 (0.42 – 1.55) 1.00 1.12 (0.62 – 2.01) 1.46 (0.81 – 2.63) 226 
3 Months 2.26 (1.10 – 4.64) 0.88 (0.47 – 1.67) 1.00 0.94 (0.53 – 1.68) 1.22 (0.68 – 2.19) 256 
6 Months 2.02 (0.98 – 4.16) 0.97 (0.52 – 1.82) 1.00 0.80 (0.45 – 1.42) 1.22 (0.68 – 2.18) 278 
1 Year 2.59 (1.23 – 5.44) 1.20 (0.64 – 2.25) 1.00 0.95 (0.54 – 1.68) 1.35 (0.75 – 2.41) 292 
*Hb = hemoglobin 
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†The cut off points for the quintiles are as follows: Male: 12.4, 13.8, 14.6, 15.6 g/dL. Female: 11.7, 12.8, 13.6, 14.5 g/dL. The variables adjusted 
for were Age, Oxford Community Stroke Project Classification, Prestroke-Ranking Score, Prior Antithrombotic Use, Coronary Heart Disease, 
Previous Stroke, Congestive Heart Failure, Atrial Fibrillation, Hypertension, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral 
Vascular Disease, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Falls, Malignancy, Dementia, Gastrointestinal Bleeding 
and Peptic Ulcer. We also adjusted for International Normalised Ratio (INR) in patients with Hemorrhagic Stroke. INR was included as a 
dichotomous categorical variable; < 1.40 vs >= 1.40. Data for the time points of 7 and 14 days have been removed for brevity. Mean ages for the 
male quintiles were 82.80, 80.48, 78.49, 78.09 and 78.38 for Quintiles 1 – 5 respectively. Mean ages for female quintiles were 83.04, 81.81, 
80.45, 78.96 and 78.06 for Quintiles 1 – 5 respectively. 
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Table [3]. Effect of Anemia and Elevated Hemoglobin on Stroke Outcomes at Different Time Points (Logistic Regression) 
 
*The cut off points were as follows: Male: 13.00, 17.00 g/dL, Female: 12.00, 15.50 g/dL. The variables adjusted for were Age, Oxford 
 Anemia Normal Elevated Hemoglobin Events 
Male - Ischemic  
Number 896 2,277 125  
Inpatient 1.75 (1.37 – 2.25) 1.00 1.85 (1.03 – 3.32) 511 
1 Month 1.86 (1.46 – 2.38) 1.00 1.79 (1.00 – 3.20) 488 
3 Months 2.18 (1.75 – 2.72) 1.00 1.86 (1.08 – 3.18) 674 
6 Months 2.25 (1.83 – 2.78) 1.00 1.46 (0.86 – 2.48) 796 
1 Year 2.25 (1.85 – 2.75) 1.00 1.50 (0.91 – 2.47) 971 
Male - Hemorrhagic   
Number 121 367 25  
Inpatient 1.33 (0.77 – 2.31) 1.00 3.30 (1.19 – 9.17) 176 
1 Month 1.42 (0.83 – 2.42) 1.00 2.90 (1.08 – 7.75) 173 
3 Months 1.39 (0.81 – 2.39) 1.00 2.08 (0.75 – 5.78) 200 
6 Months 1.64 (0.94 – 2.85) 1.00 1.56 (0.56 – 4.40) 221 
1 Year 1.76 (1.01 – 3.04) 1.00 1.56 (0.56 – 4.35) 229 
Female - Ischemic  
Number 852 2,585 216  
Inpatient 1.20 (0.97 – 1.49) 1.00 1.30 (0.87 – 1.94) 792 
1 Month 1.29 (1.04 – 1.60) 1.00 1.49 (1.00 – 2.21) 733 
3 Months 1.39 (1.14 – 1.70) 1.00 1.19 (0.81 – 1.75) 1007 
6 Months 1.44 (1.18 – 1.75) 1.00 1.12 (0.78 – 1.62) 1159 
1 Year 1.47 (1.22 – 1.77) 1.00 1.04 (0.73 – 1.48) 1328 
Female - Hemorrhagic  
Number 95 418 36  
Inpatient 1.90 (1.09 – 3.33) 1.00 2.76 (1.16 – 6.56) 229 
1 Month 1.82 (1.06 – 3.11) 1.00 2.11 (0.92 – 4.82) 226 
3 Months 1.80 (1.04 – 3.13) 1.00 2.08 (0.91 – 4.77) 256 
6 Months 2.05 (1.17 – 3.59) 1.00 2.99 (1.29 – 6.90) 278 
1 Year 2.11 (1.19 – 3.74) 1.00 2.63 (1.14 – 6.05) 292 
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Community Stroke Project Classification, Prestroke-Ranking Score, Prior Antithrombotic Use, Coronary Heart Disease, Previous Stroke, 
Congestive Heart Failure, Atrial Fibrillation, Hypertension, Hypertension, Hyperlipidemia, Diabetes Mellitus, Peripheral Vascular Disease, 
Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Falls, Malignancy, Dementia, Gastrointestinal Bleeding and Peptic Ulcer. We 
also adjusted for International Normalised Ratio (INR) in patients with Hemorrhagic Stroke. INR was included as a dichotomous categorical 
variable; < 1.40 vs >= 1.40. Data for the time points of 7 and 14 days have been removed for brevity.  
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Table [4]. Use of Prior Antithrombotic by Anemia Status and Vascular Indication (Chi-Square Test) 
 Vascular Indication Yes* Vascular Indication No 
 Anemia No Anemia P-Value Anemia No Anemia P-Value 
Male   0.971   <0.001 
No Antithrombotic 237 (34.2) 456 (65.8)  210 (16.3) 1082 (83.7)  
Antithrombotic 447 (34.3) 857 (65.7)  123 (23.6) 399 (76.4)  
Female   0.032   0.334 
No Antithrombotic 270 (28.9) 665 (71.1)  229 (17.1) 1114 (82.9)  
Antithrombotic 350 (24.9) 1,057 (75.1)  98 (19.0) 419 (81.0)  
* Indications considered were Previous Stroke, Coronary Heart Disease, Diabetes, Hypertension, Peripheral Vascular Disease, Atrial Fibrillation 
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Table [5]. Characteristics of Studies Examining the Relationship Between Anemia/Hemoglobin Levels and Stroke Outcomes 
Author Years 
Sampled 
Study 
Design 
n 
 
Exposure(s) Outcome(s) Main Result 
Bhatia et al 
[6] 
2000 – 
2001 
Prospective 116 Admission hemoglobin Mortality at 30 days Hemoglobin not associated with 
outcome 
Bussiere et al 
[16] 
2003 – 
2008 
Prospective 2,406 Admission hemoglobin 
divided into quintiles. 
Cut-offs: 100, 120, 140, 
160 g/l 
Mortality at 1 year, 
mRs at discharge 
Hemoglobin predicted mortality at 1 
year: aOR 1.39 (1.01-1.91) in 
hemoglobin <100 vs 141-160 g/l 
Chang et al 
[17] 
 
2008 – 
2010 
Prospective 106 
 
Admission hemoglobin, 
nadir hemoglobin and 
transfusion 
 
In-hospital mortality, 
length of stay and 
disability at discharge 
Admission anemia did not predict 
outcomes 
Czlonkowska 
et al [7] 
1991 – 
1992 
Prospective 345 Admission hemoglobin Mortality at 30 days Hemoglobin not associated with 
outcome 
Diedler et al 
[18] 
2004 – 
2006 
Prospective 196 Admission, mean and 
nadir hemoglobin 
mRs at discharge and 
6 months 
Admission hemoglobin did not predict 
outcomes 
Del Fabbro 
et al [28] 
2001 – 
2003 
Retrospective 890 Anemia on admission In-hospital mortality, 
survival at 1 year 
Higher hemoglobin predicted 
decreased mortality at 1 year: HR 0.98 
(0.97 – 1.00) 
Gray et al 
[27] 
1985 – 
1986 
- 122 Admission hemoglobin Mortality at 4 and 12 
weeks 
Hemoglobin not associated with 
outcome 
Hao et al [2] 2002 – 
2008 
Prospective 1,176 
 
Anemia on admission In-patient mortality, 
mortality and 
disability (mRs > 2) at 
12 months 
Anemia associated with in-patient 
mortality, 
aOR 1.66 (1.08 – 2.56) and mortality 
at 
12 months, aOR 1.56 (1.05 – 2.31) 
Huang et al 
[19] 
 
2001 – 
2003 
Prospective 
 
774 
 
Anemia on admission 
 
In-patient mortality, 
mRs at discharge, 
Stroke recurrence at 3 
years 
Anemia was associated at increased 
mortality at 3 years: aOR 2.22 (1.13–
4.39) 
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Kellert et al 
[8] 
1998 – 
2009 
Prospective 217 
 
Admission, mean and 
nadir hemoglobin 
Mortality and mRs at 
3 months 
 
Hb decrease was associated with 
increased mortality at 3 months (OR 
1.34: 1.01 – 1.76) but admission hb 
was not (OR not given) 
Kumar et al 
[20] 
 
1999 – 
2005 
Prospective 
 
685 
 
Anemia on admission 
 
Mortality at 30 days, 
ICH Volume 
Anemia is not a predictor of mortality 
on multivariable analysis OR 1.5 (0.9–
2.4) 
Kuramatsu et 
al [21] 
2006 – 
2010 
Prospective 435 
 
Anemia on admission 
 
mRs at 90 days and 1 
year 
Anemia was associated with poor 
long-term-outcome (mRS 4-6 at 1 
year): OR 7.5 
Milionis et al 
[22] 
 
2003 – 
2011 
 
Retrospective 
 
2,439 
 
Anemia on admission Mortality and 
disability at 12 
months 
Anemia associated with mortality at 
12 months: OR 2.70 (2.12 – 3.43) 
Nybo et al 
[23] 
2003 – 
2004 
- 250 
 
Anemia on admission 
 
Mortality at 6 months Anemia associated with greater risk of 
death at 6 months: OR 4.7 (1.1–8.2) 
Park et al [9] 
 
2004 – 
2009 
Prospective 
 
2,681 
 
Admission, nadir, time-
averaged and discharge 
hemoglobin 
Mortality and mRs at 
3 months 
 
Admission hemoglobin predicted 
mortality 3 months. aOR’s: Q1 vs. Q3 
was 3.74 (2.03–6.89) and Q5 vs. Q3 
was 1.99 (1.02–3.91) 
Sharma et al 
[24] 
2003 – 
2011 
 
Post hoc 
analysis  of 
RCT 
3,020 
 
Admission hemoglobin 
and hemoglobin < 13 
All-cause mortality 
 
Hb < 13g/dL was a significant 
predictor of mortality: HR 1.60 (1.22–
2.10) 
Sico et al [1] 1998 – 
2003 
Retrospective 
 
1,306 
 
Anemia on admission In-patient mortality or 
discharge to hospice 
(combined end-point) 
Anemia was associated with outcome 
in patients with less severe stroke on 
sub-group analysis, aOR: 4.17 (1.47 – 
11.90) 
Tanne et al 
[10] 
2001 – 
2002 
Prospective 859 Anemia on admission Mortality at 1 month 
and 1 year, functional 
outcome using Barthel 
Index 
aOR for mortality at 1 month, 1.90 
(1.05 – 3.43), 1 year, 1.72 (1.00 – 
2.93) 
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Wade et al 
[25] 
1977 – 
1982 
Post hoc 
analysis of 
RCT 
1,377 Hemoglobin >15 vs ≥15 
g/dl on study entry 
Fatal and non-fatal 
strokes 
No significant difference in 
hemoglobin levels amongst those who 
died compared to survivors. 
Zeng et al 
[26] 
 
2007 – 
2008 
Prospective 
 
2,513 
 
Anemia on admission Mortality and 
dependency (mRs > 2) 
at 1, 3, 6 and 12 
months 
aOR for mortality in anemic patients 
compared to non-anemic were, 6-
month 1.34 (1.01 – 1.78), 
1 year 1.33 (1.00 – 1.75) 
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Table [6]. Characteristics Determining Study Validity 
Study Method of 
Stroke 
Diagnosis 
Time of 
Mortality 
Measurement 
Method of 
Mortality 
Measurement 
Confounders Adjusted For 
in Multivariate Logistic 
Regression 
Hemoglobin Cut-
offs Used 
Stroke Types 
Considered 
Bhatia et al 
[6] 
Imaging 30 days 
 
Telephone, 
outpatient or home 
interview 
- - Both 
considered 
together 
Bussiere et 
al [16] 
Imaging 30 days, 6 
months, 1 year 
Population 
registries 
Age, sex, warfarin, INR, 
glucose, creatinine, blood 
pressure, IVH 
Quintiles. Cut-
offs;100, 120, 140, 
160,  anemia defined 
<120 g/l 
ICH Only 
Chang et al 
[17] 
 
Imaging In-hospital 
mortality 
Attending 
physician 
 
Age, nadir hemoglobin, ICH 
score, intubation 
Anemia (WHO 
definition) 
ICH Only 
Czlonkowsk
a et al [7] 
Imaging or 
autopsy 
30 days 
 
- Age, decreased consciousness, 
severity of weakness 
- Both 
considered 
together 
Diedler et al 
[18] 
Imaging In-hospital 
mortality 
Attending 
physician 
 
 
Age, ICH volume, NIHSS, 
IVH, ICU stay, mechanical 
ventilation, RBC transfusion, 
mean hemoglobin 
Anemia definition; 
<12.1 g/l for women 
<13.1 g/l for men 
ICH Only 
Del Fabbro 
et al [28] 
- In-hospital, 1 
year 
Telephone 
interview, 
population 
registries 
Age, GFR, comorbidities, 
functional status 
Anemia (WHO 
definition) 
Both 
considered 
together 
Gray et al 
[27] 
Clinical 
Evaluation 
4 weeks and 12 
weeks 
- Age, white cell count, 
haematocrit, hemoglobin, urea 
>16g/dL defined as 
elevated 
Both 
considered 
together 
Hao et al [2] Imaging 1 year - 
 
Age, sex, co-morbidities, 
smoking, alcohol, NIHSS, 
eGFR 
Anemia (WHO 
definition) 
AIS Only 
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Huang et al 
[19] 
 
Imaging 3 years 
 
Outpatient 
interview 
Age, co-morbidities Anemia (WHO 
definition) 
AIS Only 
Kellert et al 
[8] 
Imaging 3 months 
 
Telephone and 
outpatient interview 
Age, NIHSS, blood glucose, 
microcytic and hypochromic 
RBCs, leucocytosis, creatinine, 
CRP 
Anemia (WHO 
definition) 
AIS Only 
Kumar et al 
[20] 
 
Imaging 30 days 
 
Telephone 
interview, medical 
records, population 
registry 
Age, sex, warfarin, ICH 
volume, IVH, glucose, WBC 
Anemia (WHO 
definition) 
ICH Only 
Kuramatsu 
et al [21] 
Imaging 90 days and 1 
year 
 
Telephone 
interview, mailed 
questionnaire 
 
NIHSS, GCS, ICH-Score, ICH 
Volume, IVH, Graeb score, 
midline shift, hemoglobin, 
hematocrit, mechanical 
ventilation, pneumonia 
Anemia (WHO 
definition) 
ICH Only 
Milionis et 
al [22] 
 
Imaging 7 days, 3 
months, 12 
months 
 
Medical records, 
death certificate, 
population registry 
Age, sex, smoking, insurance, 
time to treatment, type of 
intervention, co-morbidities, 
prior medication, BMI, blood 
pressure, heart rate, TOAST 
Classification, metabolic 
parameters 
Anemia (WHO 
definition) 
AIS Only 
Nybo et al 
[23] 
Imaging 6 months Population registry Age, sex, co-morbidities, 
Scandinavian stroke scale 
Anemia (WHO 
definition) 
AIS Only 
Park et al 
[9] 
 
- 3 months 
 
Telephone 
interview, chart 
review 
Age, sex, blood pressure, pre-
stroke mRs, NIHSS, co-
morbidities, blood glucose, 
thrombolysis 
Pre-specified 
quintiles 
AIS Only 
Sharma et al 
[24] 
Imaging - - Age, BMI, co-morbidities, 
hemoglobin, eGFR 
Hemoglobin 
<13g/dL 
AIS Only 
Sico et al Imaging In-hospital - Age, NIHSS Hematocrit < 31% AIS Only 
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[1] 
Tanne et al 
[10] 
Imaging Mortality at 1 
and 1-year 
Population registry Age, sex, stroke type, NIHSS, 
prior disability, co-morbidities 
Anemia (WHO 
definition) 
Both 
considered 
separately 
Wade et al 
[25] 
Imaging - - - Cut-off at 15 g/dL AIS Only 
Zeng et al 
[26] 
Imaging Discharge, 30 
days, 3, 6, 12 
months 
Telephone 
interview 
Age, sex, pre-stroke mRS, 
NIHSS, BMI, GCS, ICH 
volume, glucose, co-
morbidities, antithrombotic 
use, antihypoglycemic use, 
antihyperlipidemic use, family 
history, smoking, alcohol 
Anemia (WHO 
definition) 
ICH Only 
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Table [7]. Odds Ratios From Studies Evaluating Association Between Elevated Hemoglobin and Stroke Mortality 
Ischemic Stroke 
Study Definition of Elevated 
Hemoglobin 
Mortality 
time-point 
Number of 
patients 
Odds Ratio 
Park et al [9] Pre-specified Quintile 3 months 2,681 1.99 (1.02 – 3.91) 
Current Study 
Male 
Over 17 g/dL In-patient 
1 month 
3 months 
6 months 
1 year 
3,298 1.85 (1.03 – 3.32) 
1.79 (1.00 – 3.20) 
1.86 (1.08 – 3.18) 
1.46 (0.86 – 2.48) 
1.50 (0.91 – 2.47) 
Current Study 
Female 
Over 15.5 g/dL In-patient 
1 month 
3 months 
6 months 
1 year 
3,653 1.30 (0.87 – 1.94) 
1.49 (1.01 – 2.21) 
1.19 (0.81 – 1.75) 
1.12 (0.78 – 1.62) 
1.04 (0.73 – 1.48) 
Hemorrhagic Stroke 
Study Definition of Elevated 
Hemoglobin 
Mortality 
time-point 
Number of 
patients 
Odds Ratio 
Bussiere et al 
[16] 
Over 16 g/dL 1 year 2,406 1.00 (0.74 – 1.33) 
Current Study 
Male 
Over 17 g/dL In-patient 
1 month 
3 months 
6 months 
1 year 
513 3.20 (1.19 – 9.17) 
2.90 (1.08 – 7.75) 
2.08 (0.75 – 5.78) 
1.56 (0.56 – 4.40) 
1.56 (0.56 – 4.35) 
Current Study 
Female 
Over 15.5 g/dL In-patient 
1 month 
3 months 
6 months 
1 year 
549 2.76 (1.16 – 6.56) 
2.11 (0.92 – 4.82) 
2.08 (0.91 – 4.77) 
2.99 (1.29 – 6.90) 
2.63 (1.14 – 6.05) 
 
